3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
4
Unknown
3
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
37
Thoracic
25
Head & Neck
11
Other solid neoplasm
6
Breast
5
Genitourinary
4
Dermatologic
4
Other hematologic neoplasm
3
Sarcoma
2
Gynecologic
2
CNS
2
Tumor-Agnostic
1
Myeloid
1
Lymphoid
1
Conditions
Neoplasms
1
Neoplasm Metastasis
1
Interventions
pembrolizumab
26
Specimen Handling
17
Blood Specimen Collection
17
Biopsy
16
Magnetic Resonance Spectroscopy
15
atezolizumab
11
Surveys and Questionnaires
11
Bevacizumab
9
Radiotherapy
8
Radiosurgery
8
Nivolumab
8
Fluorouracil
8
Standard of Care
7
Paclitaxel
7
Irinotecan
7
Gemcitabine
7
Cisplatin
7
olaparib
6
durvalumab
6
Palliative Care
6
Oxaliplatin
6
Leucovorin
6
Cyclophosphamide
6
Carboplatin
6
Capecitabine
6
alectinib
5
abemaciclib
5
Trastuzumab
5
Interviews as Topic
5
Exercise
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Immune Checkpoint Inhibitors
×
Tumor-Agnostic
×
Clear all
NCT06524570
2026-02-18
iFOCUS
UMC Utrecht
Phase 1
Recruiting
24 enrolled